DaVita Inc. (NYSE:DVA) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its stake in shares of DaVita Inc. (NYSE:DVA) by 3.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,214,815 shares of the company’s stock after selling 170,752 shares during the quarter. Vanguard Group Inc. owned 0.06% of DaVita worth $779,876,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Amundi increased its stake in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after buying an additional 240,126 shares during the period. FMR LLC increased its position in shares of DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its holdings in shares of DaVita by 256.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock valued at $24,301,000 after purchasing an additional 116,758 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Finally, Strategic Financial Concepts LLC acquired a new position in shares of DaVita during the fourth quarter worth $9,371,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on DVA. StockNews.com downgraded DaVita from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Barclays boosted their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $166.33.

DaVita Price Performance

Shares of NYSE DVA opened at $150.29 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The stock has a market cap of $12.02 billion, a P/E ratio of 13.99, a P/E/G ratio of 1.07 and a beta of 0.99. The stock has a 50 day moving average of $157.39 and a two-hundred day moving average of $157.52. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.